06th April 2022 | Pharma Updates
Medcis Pathlabs has been acquired by Manipal HealthMap
Manipal HealthMap announced the acquisition of Hyderabad-based Medcis Pathlabs Pvt Ltd for a majority share of 84 percent in an all-cash deal of Rs 100 crore.
Intas Pharma signed a supply deal for Ranibizumab biosimilars in the Middle East
Intas Pharmaceuticals has inked an exclusive licence and supply deal with Axantia Holding to market and sell Ranibizumab in Saudi Arabia, Jordan, Iraq, Lebanon, and the Gulf Cooperation Council countries.
In US, Omicron sub-variant BA.2 accounts for 72% of Covid-19 variants: CDC
The BA.2 sub-variant of Omicron was projected to account for roughly three out of every four coronavirus variants in the United States, according to the US National Public Health Agency.
In a European trial, Gilead's remdesivir failed to show benefit
In randomised controlled trials, two medications for COVID-19 therapies in preliminary investigations – remdesivir for hospitalised patients and camostat for people who are not gravely ill – failed to show a benefit in those groups.
According to a study, Covid-19 can have long-term effects on the brain
Researchers indicates that SARS-CoV-2 virus-infected people showed evidence of severe brain inflammation and injury, including a reduction in blood or oxygen flow into the brain, neuron destruction, and small areas of haemorrhage.
Novartis' second gene therapy production facility has been approved by the FDA
FDA has approved a Novartis manufacturing plant in North Carolina to manufacture commercial-grade gene treatments, to manufacture the complex medications.
FDA Approval for Vamorolone in DMD by end of June
Santhera Pharmaceuticals and ReveraGen BioPharma plan to file for FDA approval of vamorolone as a treatment for Duchenne muscular dystrophy in the US this year, with a filing due by the end of June.
FDA has given its approval to a treatment for uremic pruritis
FDA has approved Korsuva for the treatment of moderate to severe pruritis in people receiving hemodialysis due to chronic kidney disease. Korsuva is the first medication for this condition to be licenced by the FDA.
Novartis Vijoice approved by the FDA as the first and only medication for PROS
Vijoice has been given rapid approval by the USFDA for the treatment of adult and paediatric patients 2 years of age and older who have severe signs of PIK3CA-Related Overgrowth Spectrum (PROS) and require systemic therapy.
ViiV Healthcare received FDA approval for a once-daily HIV treatment for children
Triumeq PD, a dispersible single tablet regimen comprising dolutegravir, a once-daily medication for children living with HIV, has been approved by the FDA, according to ViiV Healthcare.